Intranasal Therapeutics makes appointment
This article was originally published in Scrip
Intranasal Therapeutics (US), a speciality pharmaceutical company developing nasally delivered preservative-free products, has named Dr Jeff Edelson executive vice-president of R&D and chief medical officer. He was previously employed by Johnson & Johnson as vice-president of internal medicine and therapeutic area head – novel therapeutics.
You may also be interested in...
The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.
The proposed rule from the US HHS that would require its agencies to review all regulations every 10 years could distract an incoming Biden administration from the COVID-19 pandemic and will “wreak havoc” on Medicare, a senior policy analyst for the Center on Budget and Policy Priorities says.
The pharmacy will be ready to begin COVID-19 vaccinations 48 hours after receiving the vaccine, Merlo said, outlining plans for a mass vaccination effort that will include online appointments.